# Oral Aripiprazole Open-Label Rollover Study

> **NCT01001702** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 85 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT01001702
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2013-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01001702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01001702, "Oral Aripiprazole Open-Label Rollover Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01001702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*